Histogen (HSTO) to Explore Strategic Alternatives

Go back to Histogen (HSTO) to Explore Strategic Alternatives

Histogen to Explore Strategic Alternatives

July 5, 2023 4:05 PM UTC

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodys natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital... More